Trial Profile
A Two-way Crossover Study to Evaluate the Safety and Pharmacokinetics of Quinidine Sulfate Alone (200 mg Orally q2h to a Maximum of 1,000 mg), Dabigatran Etexilate Alone (150 mg BID for Three Days), and the Co-administration of Dabigatran Etexilate (150 mg BID) With Quinidine Sulfate (200 mg q2h)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Quinidine
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jun 2014 New trial record